FIND said it will announce agreements that will enable the distribution of more than 250 million rapid antigen tests per year to low- and middle-income countries.
The company said it would use the funding in part to expand its commercial teams in the US and China, as well as to pursue Chinese regulatory approvals.
The assay can be used to determine the immune status of COVID-19 patients and individuals who have been vaccinated against the virus, the company said.
Chia Tai Tianqing Pharmaceutical Group has agreed to copromote Genetron's HCCscreen test in hospitals where the pharma firm has an established presence.
Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.